Stockholders approved an amendment to the Articles of Incorporation to increase authorized common stock from 14,583,333 to 150,000,000 shares. The company held a special meeting on May 27, 2026, where 65.27% of outstanding shares were represented. Shareholders ratified the appointment of Kesselman & Kesselman C.P.A.s as the independent auditor for the 2025 fiscal year. The company confirmed the approval of a Convertible Loan Agreement dated September 10, 2025, involving Theracell Laboratories IKE and Alpha Prosperity Fund SPC.